Hims & Hers Pulls Back GLP-1 Weight-Loss Pill Shortly afterward, Hims & Hers Health abruptly abandoned its plan to launch a compounded version oral weight-loss pill priced as low as $49/month, backing off within days amid regulatory pressure and industry backlash
Keynesplein 1, 1066EP Amsterdam, the Kingdom of the Netherlands
Betul Hatipoglu, director of the Center for Diabetes, Obesity and Metabolism at Case Western Reserve University and of the Diabetes and Obesity Center at University Hospitals Cleveland Medical Center, says microdosing Ozempic, Zepbound or another GLP-1 drug might mean: Taking a lower dose than what was prescribed or studied in clinical trials Taking a half-dose every few days instead of a full dose once weekly Taking a full dose less often, such as every 10 or 14 days instead of every seven While these approaches are often grouped together online under the umbrella of "microdosing," they're not exactly the same thing
Age shapes expectations and experiences Satisfaction also varies sharply by age
Marston, Eastern District of Pennsylvania Number of Cases: Approximately 2,947 pending cases (and growing rapidly) Defendants: Novo Nordisk and Eli Lilly Covered Drugs: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Victoza, Saxenda, Trulicity Key Developments: August 15, 2025 - Landmark Ruling: Judge Marston ruled that gastroparesis claims require objective diagnostic testing (gastric emptying scan)
Maya F, Andrew N, Kimberly CT
